Some Black women with hormone receptor (HR)-positive/HER2-negative breast cancer had worse outcomes compared with White women despite having similar genetic recurrence risk scores, according to data from the 2022 San Antonio Breast Cancer Symposium. Yara Abdou, MD, assistant professor at the University of North Carolina at Chapel Hill and Lineberger Comprehensive Cancer Center, presented results of an analysis of clinical outcomes respective to race and ethnicity in women enrolled in the RxPONDER trial. The trial aimed to assess the value of the 21-gene recurrence score (RS) in patients with ...
SABCS 2022
The San Antonio Breast Cancer Symposium (SABCS) is the largest and most prestigious scientific gathering on breast cancer research. Topics cover new treatments, patient care, surgical and reconstructive techniques, health equity, telemedicine, and more. Find highlights from the sessions that are most relevant to oncology nurses.
Advertisement
Results from the DESTINY-Breast03 study indicate survival advantage with the antibody drug conjugate.
The local recurrence rates were optimistic for women with multiple ipsilateral breast cancer in one clinical trial.
Advertisement
Panelists discuss data from the ADEPT trial, port considerations, and their hopes for the future of breast cancer therapy.
Panelists discuss how nurses can maximize opportunities for connection as they treat patients with breast cancer.
The panelists discuss clinical trial data and patient preferences surrounding subcutaneous versus IV administration routes.
Panelists discuss how subcutaneous treatments can mitigate time toxicity and improve quality of life.
Panelists discuss how treatment options have changed and if indefinite therapy is still needed for certain patients.
Panelists discuss how to help patients understand the diagnosis and navigate treatment options.
